1. Adverse event management in patients with relapsed and refractory multiple myeloma taking pomalidomide plus low‐dose dexamethasone: A pooled analysis. (14th June 2017) Authors: Moreau, Philippe; Dimopoulos, Meletios A.; Richardson, Paul G.; Siegel, David S.; Cavo, Michele; Corradini, Paolo; Weisel, Katja; Delforge, Michel; O'Gorman, Peter; Song, Kevin; Chen, Christine; Bahlis, Nizar; Oriol, Albert; Hansson, Markus; Kaiser, Martin; Anttila, Pekka; Raymakers, Reinier; Joa... Journal: European journal of haematology Issue: Volume 99:Number 3(2017) Page Start: 199 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Anti‐myeloma potential of ruxolitinib in co‐existing JAK2V617F‐positive smouldering myeloma and polycythaemia vera. (20th February 2020) Authors: Lee, Holly; McCulloch, Sylvia; Mahe, Etienne; Shafey, Mona; Rashid‐Kolvear, Fariborz; Khan, Faisal; Prajapati, Dwip; Neri, Paola; Duggan, Peter; Tay, Jason; Bahlis, Nizar; Jimenez‐Zepeda, Victor H Journal: British journal of haematology Issue: Volume 189:Number 3(2020) Page Start: e114 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Chimeric Antigen Receptor-T Cell Mediated Bilateral Facial Nerve Palsy: A Case Report. (July 2023) Authors: Patrick, Natalya; Bahlis, Nizar; Peters, Steven Journal: Neurohospitalist Issue: Volume 13:Number 3(2023) Page Start: 308 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Co-existent B-cell and plasma cell neoplasms: a case series providing novel clinical insight. Issue 3 (3rd March 2016) Authors: Jamani, Kareem; Duggan, Peter; Neri, Paola; Bahlis, Nizar; Jimenez-Zepeda, Victor H. Journal: Leukemia & lymphoma Issue: Volume 57:Issue 3(2016:Mar.) Page Start: 557 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Continuous lenalidomide and low‐dose dexamethasone in patients with transplant‐ineligible newly diagnosed MM: FIRST trial subanalysis of Canadian/US patients. (13th October 2020) Authors: Belch, Andrew; Bahlis, Nizar; White, Darrell; Cheung, Matthew; Chen, Christine; Shustik, Chaim; Song, Kevin; Tosikyan, Axel; Dispenzieri, Angela; Anderson, Kenneth; Brown, Diane; Robinson, Suzanne; Srinivasan, Shankar; Facon, Thierry Journal: Cancer medicine Issue: Volume 9:Number 23(2020) Page Start: 8923 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial. Issue 11 (November 2021) Authors: Facon, Thierry; Kumar, Shaji K; Plesner, Torben; Orlowski, Robert Z; Moreau, Philippe; Bahlis, Nizar; Basu, Supratik; Nahi, Hareth; Hulin, Cyrille; Quach, Hang; Goldschmidt, Hartmut; O'Dwyer, Michael; Perrot, Aurore; Venner, Christopher P; Weisel, Katja; Mace, Joseph R; Raje, Noopur; Tiab, Mourad... Journal: Lancet oncology Issue: Volume 22:Issue 11(2021) Page Start: 1582 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Immunoparesis and polyclonal immunoglobulin recovery after auto-SCT for patients with multiple myeloma treated at a single institution. Issue 8 (3rd August 2018) Authors: Jimenez-Zepeda, Victor H.; Duggan, Peter; Neri, Paola; Chaudhry, Ahsan; Tay, Jason; Bahlis, Nizar Journal: Leukemia & lymphoma Issue: Volume 59:Issue 8(2018) Page Start: 1920 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Selinexor, daratumumab, and dexamethasone in patients with relapsed or refractory multiple myeloma. Issue 1 (8th November 2020) Authors: Gasparetto, Cristina; Lentzsch, Suzanne; Schiller, Gary; Callander, Natalie; Tuchman, Sascha; Chen, Christine; White, Darrell; Kotb, Rami; Sutherland, Heather; Sebag, Michael; Baljevic, Muhamed; Bensinger, William; LeBlanc, Richard; Venner, Chris; Bahlis, Nizar; Rossi, Adriana; Biran, Noa; Sheeha... Journal: EJHaem Issue: Volume 2:Issue 1(2021) Page Start: 56 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial. Issue 5 (May 2020) Authors: Mateos, Maria-Victoria; Nahi, Hareth; Legiec, Wojciech; Grosicki, Sebastian; Vorobyev, Vladimir; Spicka, Ivan; Hungria, Vania; Korenkova, Sibirina; Bahlis, Nizar; Flogegard, Max; Bladé, Joan; Moreau, Philippe; Kaiser, Martin; Iida, Shinsuke; Laubach, Jacob; Magen, Hila; Cavo, Michele; Hulin, Cyri... Journal: Lancet Issue: Volume 7:Issue 5(2020) Page Start: e370 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Suboptimal response for AL amyloidosis: is it time for early switch? Experience from a single amyloid program. (3rd July 2022) Authors: Puckrin, Robert; Lee, Holly; Tay, Jason; Duggan, Peter; McCulloch, Sylvia; Neri, Paola; Bahlis, Nizar; Jimenez-Zepeda, Victor H. Journal: Amyloid Issue: Volume 29:Number 3(2022) Page Start: 208 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗